Ozempic (Semaglutide): How It Works, Side Effects, and Cost

What Ozempic Is

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. The FDA first approved it on December 5, 2017, for glycemic control in adults with type 2 diabetes 1Ref 1Novo Nordisk A/S (2023).OZEMPIC (semaglutide) injection — Full Prescribing Information.FDA approval date (December 5, 2017), approved indications, mechanism of action, black box warning for thyroid C-cell tumors, contraindications (MTC/MEN 2), dosing schedule, GI adverse event frequency (~15–20% nausea). In January 2020, a second indication was approved: reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease 1Ref 1Novo Nordisk A/S (2023).OZEMPIC (semaglutide) injection — Full Prescribing Information.FDA approval date (December 5, 2017), approved indications, mechanism of action, black box warning for thyroid C-cell tumors, contraindications (MTC/MEN 2), dosing schedule, GI adverse event frequency (~15–20% nausea). A third indication arrived in January 2025: reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease 3Ref 3Perkovic V, et al. (2024).Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.FLOW trial: semaglutide reduced composite kidney endpoint (kidney failure, ≥50% eGFR decline, kidney-related or CV death) by 24% vs. placebo — basis for the January 2025 FDA CKD approval.

Ozempic is the 0.5 mg, 1 mg, and 2 mg once-weekly injection. It is distinct from Wegovy, which is the same molecule at a higher 2.4 mg dose and carries a separate FDA approval for chronic weight management. Ozempic is not FDA-approved for weight loss, though it is sometimes prescribed off-label for that purpose.

How Ozempic Works

GLP-1 is a hormone the small intestine releases after a meal. Ozempic mimics that hormone and acts on three sites simultaneously:

• Pancreas: Stimulates insulin secretion when blood glucose is elevated and suppresses glucagon (the hormone that raises blood sugar). This glucose-dependent mechanism means it rarely causes hypoglycemia on its own.
• Brain: Acts on hypothalamic appetite centers to reduce hunger and increase satiety signals.
• Stomach: Slows gastric emptying, so food moves through more slowly and the sense of fullness persists longer.

In the landmark SUSTAIN 6 cardiovascular outcomes trial, semaglutide reduced HbA1c by 1.1 percentage points (0.5 mg dose) and 1.4 percentage points (1 mg dose) from a baseline of approximately 8.7%, compared with 0.4 points on placebo over 104 weeks 2Ref 2Marso SP, Bain SC, Consoli A, et al. (2016).Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.SUSTAIN 6 trial: HbA1c reduction of 1.1 pp (0.5 mg) and 1.4 pp (1 mg) vs. 0.4 pp placebo; MACE reduction HR 0.74 (95% CI 0.58–0.95) — basis for the 2020 cardiovascular indication. Both doses also produced significant body weight reductions as a secondary effect of appetite suppression.

Cardiovascular Benefits

Ozempic has two FDA-approved cardiovascular indications backed by large trials.

Type 2 diabetes with established CVD: The SUSTAIN 6 trial (3,297 adults) found semaglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 26% versus placebo (HR 0.74; 95% CI 0.58–0.95) 2Ref 2Marso SP, Bain SC, Consoli A, et al. (2016).Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.SUSTAIN 6 trial: HbA1c reduction of 1.1 pp (0.5 mg) and 1.4 pp (1 mg) vs. 0.4 pp placebo; MACE reduction HR 0.74 (95% CI 0.58–0.95) — basis for the 2020 cardiovascular indication.

Obesity without diabetes: The SELECT trial (17,604 adults with prior CVD and BMI ≥ 27, no diabetes) found semaglutide 2.4 mg reduced the same MACE composite by 20% over ~40 months (6.5% vs. 8.0%; HR 0.80; 95% CI 0.72–0.90; P < 0.001) 4Ref 4Lincoff AM, et al. (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial (17,604 adults, obesity + prior CVD, no diabetes): semaglutide 2.4 mg reduced MACE by 20% vs. placebo (6.5% vs. 8.0%; HR 0.80; 95% CI 0.72–0.90; P<0.001); mean weight loss ~10.2% vs. 1.5% at 208 weeks. For patients with an established cardiovascular indication, this benefit is an independent reason to weigh continued use even when weight goals are met.

Side Effects

Common (affecting more than 1 in 10 users): - Nausea — most frequent, especially in the first 4–8 weeks and after dose increases; reported in approximately 15–20% of patients 1Ref 1Novo Nordisk A/S (2023).OZEMPIC (semaglutide) injection — Full Prescribing Information.FDA approval date (December 5, 2017), approved indications, mechanism of action, black box warning for thyroid C-cell tumors, contraindications (MTC/MEN 2), dosing schedule, GI adverse event frequency (~15–20% nausea) - Diarrhea - Vomiting - Constipation - Abdominal pain

GI effects are the main reason people discontinue Ozempic. They typically improve over time. Starting at the lowest dose and increasing slowly, eating smaller meals, and avoiding high-fat foods can help.

Less common but notable: - Decreased appetite (therapeutic in weight-loss use; can cause under-eating in some diabetes patients) - Injection-site redness or itching - Transient increase in heart rate (average 5–10 bpm) - Hypoglycemia — low blood sugar is rare with Ozempic alone but increases when combined with a sulfonylurea or insulin

Rare but serious — seek care promptly: - Pancreatitis: severe, persistent abdominal pain radiating to the back - Gallbladder disease, including gallstones - Acute kidney injury, often from dehydration during GI illness - Severe allergic reaction: rash, swelling, difficulty breathing - Diabetic retinopathy: people with pre-existing eye disease may notice worsening with rapid blood sugar improvement; new vision changes should be reported to an eye doctor

FDA Black Box Warning: In animal studies, semaglutide caused thyroid C-cell tumors. Human risk is unknown. Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1Ref 1Novo Nordisk A/S (2023).OZEMPIC (semaglutide) injection — Full Prescribing Information.FDA approval date (December 5, 2017), approved indications, mechanism of action, black box warning for thyroid C-cell tumors, contraindications (MTC/MEN 2), dosing schedule, GI adverse event frequency (~15–20% nausea).

Do You Have to Take Ozempic Forever?

For most people, the answer is: ongoing use is necessary to maintain the benefits.

The STEP 4 trial provides the clearest evidence. Participants who completed a 20-week semaglutide run-in (losing an average 10.6% of body weight) were then randomized to continue semaglutide or switch to placebo. Over the following 48 weeks, the semaglutide group lost an additional 7.9% of body weight, while the placebo group gained 6.9% — a 14.8 percentage-point difference 5Ref 5Rubino D, Abrahamsson N, Davies M, et al. (2021).Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.STEP 4 trial: after 20-week run-in (−10.6% body weight), placebo group gained 6.9% over next 48 weeks while semaglutide group lost additional 7.9% (14.8 pp difference, P<0.001) — demonstrates weight regain on discontinuation. Blood sugar control and other metabolic markers followed a similar pattern.

Why weight returns: Obesity and type 2 diabetes are chronic conditions. Semaglutide suppresses appetite while it is present; when removed, appetite-regulating hormones reassert themselves. This parallels stopping a blood pressure medication — the underlying condition returns.

Exceptions: A minority of patients who make significant lifestyle changes during treatment maintain some benefit after stopping. This is not the typical outcome. Clinicians generally treat semaglutide as a long-term medication, similar to statins or antihypertensives, rather than a time-limited course.

When stopping makes sense: Cost, pregnancy, or intolerable side effects may require discontinuation. Close monitoring of blood sugar and weight after stopping is appropriate, and a prescriber can help plan a supervised transition.

Dosing and How It Is Given

Ozempic is injected once weekly into the abdomen, thigh, or upper arm using a prefilled auto-injector pen. The standard titration schedule is 1Ref 1Novo Nordisk A/S (2023).OZEMPIC (semaglutide) injection — Full Prescribing Information.FDA approval date (December 5, 2017), approved indications, mechanism of action, black box warning for thyroid C-cell tumors, contraindications (MTC/MEN 2), dosing schedule, GI adverse event frequency (~15–20% nausea):

• Weeks 1–4: 0.25 mg/week (starter dose to improve tolerability; not the therapeutic dose)
• Week 5 onward: 0.5 mg/week
• If further control is needed (at 4+ weeks on 0.5 mg): 1 mg/week
• Maximum dose: 2 mg/week

The injection can be given on any day of the week and at any time, with or without food. Rotating the injection site each week reduces the chance of skin irritation.

Cost and Coverage

Ozempic lists at approximately $935–$1,000 per month without insurance. Several programs reduce that cost:

• NovoCare savings card (commercial insurance): Eligible patients pay as little as $25/month. Not available for Medicare, Medicaid, or other government plans.
• NovoCare direct-pay: Uninsured patients can access lower doses starting at $199/month for new patients, then $349/month.
• Novo Nordisk Patient Assistance Program: Ozempic at no cost for qualifying patients with household income at or below 400% of the federal poverty level.

Medicare Part D covers Ozempic for its diabetes and cardiovascular indications with prior authorization but does not cover it for weight loss alone. Off-label use for weight loss has faced increasing insurer scrutiny; Wegovy is the on-label semaglutide option for that indication. Compounded semaglutide, widely available during the 2022–2025 FDA shortage, has become more restricted since the FDA declared the shortage resolved in 2025.